Hamsyl (peg-aspargase biosimilar) / Emcure - LARVOL DELTA

Experience with Generic Pegylated L-asparaginase in Children with Acute Lymphoblastic Leukemia from a Tertiary Care Oncology Center in South India. (PubMed, South Asian J Cancer) - "Two children had pancreatitis, and one child had central venous thrombosis. Conclusion  The generic pegylated L-asparaginase (Hamsyl) was effective and safe for use in pediatric ALL."

Journal • Acute Lymphocytic Leukemia • Allergy • Cardiovascular • Hematological Disorders • Hematological Malignancies • Immunology • Leukemia • Oncology • Pancreatitis • Pediatrics • Thrombosis • Venous Thromboembolism

[VIRTUAL] A RANDOMIZED, PARALLEL GROUP, OPEN LABEL BIOEQUIVALENCE TRIAL OF INTRAMUSCULAR PEGASPARGASE IN PATIENTS WITH RELAPSED ACUTE LYMPHOBLASTIC LEUKEMIA (SIOP 2020) - "In 2014, the first generic of pegaspargase (Hamsyl®) was approved for use as a second line option for ALL in India. Conclusions Generic and Reference Pegaspargase had equivalent pharmacokinetics with comparable safety. This could be a safe and cost-effective alternative for patients with ALL especially in low- and middle-income countries."

Clinical • Acute Lymphocytic Leukemia • Allergy • Hematological Malignancies • Oncology • Pediatrics

Randomized, Parallel Group, Open-Label Bioequivalence Trial of Intramuscular Pegaspargase in Patients With Relapsed Acute Lymphoblastic Leukemia. (PubMed, JCO Glob Oncol) - "Generic and reference pegaspargase had equivalent pharmacokinetics with comparable safety. This could be a safe and cost-effective alternative for patients with ALL, especially in low- and middle-income countries."

Clinical • Journal • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • Pediatrics